I believe that a US Patent announcement is imminent:
http://www.primabiomed.com.au/investor/pdf/2015/29_05_15_announcement.pdf
IMP321 has demonstrated a 50% response rate in the treatment of metastatic breast cancer when compared to Paclitaxel monotherapy (25%). The drug has reached Stage IIB (safety and efficacy); if it holds up in Stage III (efficacy), it is likely to gain express approval from the US FDA. If this occurs, IMP321 would be worth billions. Paclitaxel is now out of patent and it still generates $1.5 Billion+ in sales annually. Imagine the revenue IMP321 would generate on Patent?
Stage IIB results were released last week and confirm IIA outcomes:
http://www.primabiomed.com.au/investor/pdf/2016/FirstAIPACDataJune2016finaldraftclean.pdf
I believe that a US Patent announcement is imminent:...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |